WeightWatchers is struggling. Launched in the early 1960s, the brand grew by helping members shed pounds through behavioural change programmes. Then, GLP-1 anti-obesity drugs hit the market, long-time spokesperson and board member Oprah Winfrey announced her departure, and the company’s credit rating was downgraded. FT reporter Anna Mutoh examines whether WeightWatchers’ latest strategy can produce the turnaround investors are hoping for.

Clip from Lionsgate Television

- - - - - - - - - - - - - - - - - - - - - - - - - -

For further reading:

WeightWatchers faces an era when weight loss comes in a syringe

Behold the Ozempic effect on business

The race to develop the next generation of weight-loss drugs

- - - - - - - - - - - - - - - - - - - - - - - - - -

On X, follow Anna Mutoh (@anna_mutoh) and Michela Tindera (@mtindera07), or follow Michela on LinkedIn for updates about the show and more.

Read a transcript of this episode on FT.com

Hosted on Acast. See acast.com/privacy for more information.

Can WeightWatchers survive the Wegovy era?

The Story of Money